ST2介导的中性气道炎症:对于患有失控喘的患者来说,是一种治疗标
Quang Luu Quoc1,2, Thi Bich Tra Cao1,2, Jae-Hyuk Jang1
1Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea.
Allergy, asthma & immunology research
|January 23, 2024
概括
介质素-33 (IL-33) 通过ST2受体激活中性粒细胞和巨细胞,在失控的喘中引发呼吸道炎症. 向ST2可以治疗这种严重的中性友性喘.
科学领域:
- 免疫学 免疫学 免疫学
- 呼吸系统医学 呼吸系统医学
- 分子生物学分子生物学
背景情况:
- 抑制瘤发生性2 (ST2) 与2型低喘和中性恋炎症有关.
- 在中性粒细胞激活中,ST2的确切作用需要进一步阐明.
研究的目的:
- 研究ST2及其连接体IL-33在喘中中性友气道炎症中的作用.
- 评估ST2在中性粒细胞和巨细胞激活中的功能.
主要方法:
- 在105名喘患者 (控制,部分控制,不受控制) 和104名健康对照中比较血清溶解性ST2 (sST2) 和IL-33水平.
- 在中性粒细胞和巨细胞中评估ST2功能,ex vivo和in vivo.
- 使用了用抗ST2抗体治疗中性友性喘的小鼠模型.
主要成果:
- 血清上升的sST2水平与喘控制较差和肺功能减弱相关.
- 在不受控制的喘中,中性粒细胞的ST2受体表达高于中性粒细胞.
- 刺激IL-33增加了活性氧物种和中性粒细胞外细胞陷的形成.
- 在小鼠中,抗ST2治疗减少了肺炎和促炎细胞因子.
结论:
- 通过ST2,IL-33激活中性粒细胞和巨细胞,导致中性粒细胞呼吸道炎症和喘控制不良.
- 在失控喘中,ST2代表了中性友气道炎症的潜在治疗标.
更多相关视频
相关概念视频
Antiasthma Drugs: Leukotriene Modifiers
300
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
300
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
298
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
298
Asthma-II: Pathophysiology and Classification
2.7K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.7K
Asthma: Pathogenesis and Management
403
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
403
Antiasthma Drugs: β2-Adrenoceptor Agonists
267
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
267
Drugs Used in Lower Respiratory Disorders: Overview
442
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
442


